Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Director departure
Asset disposition
Inv. presentation
Quarterly results
Credit agrmnt [a]
|
|
Xtant Medical Holdings, Inc. (XTNT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/08/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of September 30, 2021 As of December 31, 2020 ASSETS Current Assets: Cash and cash equivalents $ 18,175 $ 2,341 Restricted Cash 439 - Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $576 and $653, respectively 6,321 6,880 Inventories 19,708 21,408 Prepaid and other current assets 945 736 Total current assets 45,588 31,365 Property and equipment, net 4,971 4,347 Right-of -use asset, net 1,369 1,690 Goodwill 3,205 3,205 Intangible assets, net 414 457 Other assets 244 402 Total Assets $ 55,791 $ 41,466 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 2,355 $ 2,947 Accrued liabilities 4,079 5,462 Current portion of lease liability 451 423 Finance lease obiligat..." |
|
| 08/05/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2021 December 31, 2020 ASSETS Current Assets: Cash and cash equivalents $ 18,643 $ 2,341 Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $554 and $653, respectively 7,027 6,880 Inventories 21,641 21,408 Prepaid and other current assets 1,165 736 Total current assets 48,476 31,365 Property and equipment, net 4,666 4,347 Right-of -use asset, net 1,585 1,690 Goodwill 3,205 3,205 Intangible assets, net 443 457 Other assets 322 402 Total Assets $ 58,697 $ 41,466 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 2,490 $ 2,947 Accrued liabilities 4,569 5,462 Current portion of lease liability 431 423 Current portion of finance lease obligations 30 20 Current..." |
|
| 02/24/2021 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of December 31, 2020 As of December 31, 2019 ASSETS Current Assets: Cash and cash equivalents $ 2,341 $ 5,237 Trade accounts receivable, net of allowance for credit losses of $653 and doubtful accounts of $500, respectively 6,880 10,124 Inventories 21,408 16,101 Prepaid and other current assets 736 784 Total current assets 31,365 32,246 Property and equipment, net 4,347 4,695 Right-of -use asset, net 1,690 2,100 Goodwill 3,205 3,205 Intangible assets, net 457 515 Other assets 402 394 Total Assets $ 41,466 $ 43,155 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 2,289 $ 2,188 Accrued liabilities 6,120 6,632 Current portion of lease liability 423 394 Finance lease obiligations 20 176 Current port..." |
|
| 10/29/2020 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of September 30, 2020 As of December 31, 2019 ASSETS Current Assets: Cash and cash equivalents $ 2,741 $ 5,237 Trade accounts receivable, net of allowance for credit losses of $746 and doubtful accounts of $500, respectively 7,317 10,124 Inventories 20,671 16,101 Prepaid and other current assets 1,656 784 Total current assets 32,385 32,246 Property and equipment, net 4,122 4,695 Right-of -use asset, net 1,799 2,100 Goodwill 3,205 3,205 Intangible assets, net 471 515 Other assets 412 394 Total Assets $ 42,394 $ 43,155 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 2,814 $ 2,188 Accrued liabilities 6,043 6,632 Current portion of lease liability 415 394 Current portion of financing lease obligati..." |
|
| 08/03/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 03/05/2020 |
8-K
| Quarterly results |
| 11/07/2019 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of September 30, 2019 As of December 31, 2018 ASSETS Current Assets: Cash and cash equivalents $ 5,749 $ 6,797 Trade accounts receivable, net of allowance for doubtful accounts of $1,375 and $2,140, respectively 9,121 9,990 Inventories 16,025 17,301 Prepaid and other current assets 714 589 Total current assets 31,609 34,677 Property and equipment, net 5,068 7,174 Right-of -use asset, net 2,198 - Goodwill 3,205 3,205 Intangible assets, net 529 573 Other assets 428 793 Total Assets $ 43,037 $ 46,422 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 2,249 $ 6,465 Accrued liabilities 6,196 5,150 Warrant derivative liability 17 10 Current portion of lease liability 387 - Current portion of financing l..." |
|
| 08/08/2019 |
8-K
| Quarterly results |
| 05/15/2019 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. Condensed Consolidated Balance Sheets As of March 31, 2019 As of December 31, 2018 ASSETS Current Assets: Cash and cash equivalents $ 7,097 $ 6,797 Trade accounts receivable, net of allowance for doubtful accounts of $2,161 and $2,140, respectively 9,493 9,990 Inventories, net 16,526 17,301 Prepaid and other current assets 464 589 Total current assets 33,580 34,677 Property and equipment, net 6,382 7,174 Right-of-use asset, net 2,568 — Goodwill 3,205 3,205 Intangible assets, net 558 573 Other assets 772 793 Total Assets $ 47,065 $ 46,422 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 6,036 $ 6,465 Accrued liabilities 4,429 5,150 Warrant derivative liability 25 10 Current portion of lease liability 374 — Current portion of financing l..." |
|
| 04/01/2019 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of December 31, 2018 As of December 31, 2017 ASSETS Current Assets: Cash and cash equivalents $ 6,797 $ 2,856 Trade accounts receivable, net of allowance for doubtful accounts of $2,140 and $2,135, respectively 9,990 12,714 Inventories, net 17,301 22,423 Prepaid and other current assets 589 1,706 Total current assets 34,677 39,699 Property and equipment, net 7,174 9,913 Goodwill 3,205 41,535 Intangible assets, net 573 13,826 Other assets 793 732 Total Assets $ 46,422 $ 105,705 LIABILITIES & STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable $ 6,465 $ 9,316 Accounts payable - related party - 160 Accrued liabilities 5,150 15,845 Warrant derivative liability 10 131 Current portion of capital lease obligations 426 36..." |
|
| 08/07/2018 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results|
Docs:
|
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Revenue Orthopedic product sales $ 21,371,030 $ 21,311,322 $ 43,367,345 $ 42,119,357 Other revenue 37,130 150,248 123,484 319,548 Total Revenue 21,408,160 21,461,570 43,490,829 42,438,905 Cost of sales 7,880,639 6,758,071 14,438,241 13,635,338 Gross Profit 13,527,521 14,703,499 29,052,588 28,803,567 Operating Expenses General and administrative 4,526,543 3,899,280 8,654,811 7,383,992 Sales and marketing 11,137,082 10,420,028 22,134,101 20,932,994 Research and development 640,045 783,897 1,338,680 1,683,472 Depreciation and amortization 1,469,603 1,216,696 2,750,568 2,425,030 Acquisition and integration related expenses — 450,755 — 752,528 Se..." |
|
| 11/07/2016 |
8-K
| Quarterly results |
| 08/01/2016 |
8-K
| Quarterly results|
Docs:
|
"Fourth Amendment to Amended and Restated Credit Agreement, by and among Bacterin International, Inc., ROS Acquisition Offshore LP and OrbiMed Royalty Opportunities II, LP",
"XTANT MEDICAL HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited For the Six months ended June 30, 2016 2015 Operating activities: Net loss $ $ Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,649,361 446,799 Non-cash Interest 2,371,919 363,375 Non-cash consideration associated with stock purchase agreement 0 558,164 /Loss on sale of fixed assets 0 Amortization of debt discount 169,971 848,773 Non-cash consulting expense/stock option expense 271,374 444,395 Provision for losses on accounts receivable and inventory 432,781 Change in derivative warrant liability 476,289 Changes in operating assets and liabilities: Accounts receivable 207,934 Inventories 209,760 Prepaid and other assets Accounts payable 3,652,11..." |
|
| 11/12/2015 |
8-K
| Quarterly results |
| 05/05/2015 |
8-K
| Quarterly results|
Docs:
|
"BACTERIN INTERNATIONAL HOLDINGS, INC. Consolidated Statements of Operations For the Three Months Ended March 31, 2015 2014 % of % of Amount Revenue Amount Revenue Revenue Tissue sales $ 9,277,047 97.6 % $ 8,751,345 98.2 % Royalties and other 226,067 2.4 % 161,625 1.8 % Total Revenue 9,503,114 100.0 % 8,912,970 100.0 % Cost of sales 3,472,477 36.5 % 3,410,705 38.3 % Gross Profit 6,030,637 63.5 % 5,502,265 61.7 % Operating Expenses General and administrative 2,425,167 25.5 % 2,288,803 25.7 % Sales and marketing 4,713,672 49.6 % 4,055,204 45.5 % Research and development 433,561 4.6 % 254,583 2.9 % Depreciation and amortization 124,111 1.3 % 75,148 0.8 % Non-cash consulting expense 66,796 0.7 % 20,527 0.2 % Total Operating Expenses 7,763,307 81.7 % 6,694,265 75.1 % Loss from Operations before ..." |
|
| 03/17/2015 |
8-K
| Quarterly results|
Docs:
|
"Registration Rights Agreement, between Bacterin International Holdings, Inc. and Aspire Capital Fund, LLC",
"Common Stock Purchase Agreement, between Bacterin International Holdings, Inc. and Aspire Capital Fund, LLC",
"Fourth Quarter Highlights: · Total revenue increased to $9.1 million from $8.3 million in Q4 2013, an increase of 10.0% over the prior year · Gross profit increased to $5.8 million compared to $4.1 million in Q4 2013, an increase of 41.2% over the prior year · Gross margins improved to 63.5%, an increase from 49.5% reported in the fourth quarter of 2013 · Loss from operations before impairment decreased to $1.6 million from $2.8 million in the prior year BELGRADE, Mont., March 17, 2015 -- Bacterin International Holdings, Inc. , a leader in the development of bone graft material, today reported financial results for the fourth quarter and full year ended December 31, 2014. The Company reported annual revenues of approximately $35.3 million and a net loss for the ..." |
|
| 11/05/2014 |
8-K
| Quarterly results |
| 08/12/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Quarterly results |
| 03/19/2014 |
8-K
| Quarterly results |
| 11/07/2013 |
8-K
| Form 8-K - Current report |
| 08/06/2013 |
8-K
| Quarterly results |
| 05/09/2013 |
8-K
| Form 8-K - Current report |
| 03/26/2013 |
8-K
| Quarterly results |
| 11/07/2012 |
8-K
| Quarterly results |
| 08/09/2012 |
8-K
| Form 8-K - Current report |
| 05/03/2012 |
8-K
| Form 8-K - Current report |
| 03/22/2012 |
8-K
| Form 8-K - Current report |
|
|
|